A Phase 3 interventional study of CTAP101 Capsules and Calcitriol in Chronic Kidney Disease, Hyperparathyroidism, Secondary and Vitamin D Deficiency, sponsored by OPKO Health, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-29.
Sponsored by OPKO Health, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.
Only subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 are eligible to participate in this extension study. This is a phase 3, open-label study of CTAP101 Capsules, with and without add-on vitamin D hormone therapy.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
This study's enrollment of 298 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
Drug: CTAP101 Capsules
CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
Drug: CTAP101 Capsules · Drug: Calcitriol
CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
Drug: CTAP101 Capsules · Drug: Doxercalciferol
CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
Drug: CTAP101 Capsules · Drug: Paricalcitol
At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
Also known as: Calcifediol
At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
Also known as: calcifediol
At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
Also known as: calcifediol
At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
Also known as: calcifediol
Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
Number of subjects in the intent to treat population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders
Time frame: up to 6 months
Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
Number of subjects in the per protocol population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders
Time frame: up to 6 months
Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)
Number of Participants in the Intent to Treat Population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)
Time frame: up to 6 months
Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)
Number of Participants in the per protocol population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)
Time frame: up to 6 months
Subjects could enroll in extension study after completing trials CTAP101-CL-3001 or CTAP101-CL-3002. Subjects from 68 sites participated with at least 1 subject enrolled in the extension per site. Three sites participated in both blinded trials.
| Milestone | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Started | 103 | 153 | 42 |
| Completed | 91 | 130 | 39 |
| Not completed | 12 | 23 | 3 |
| Withdrew: Withdrawal by subject | 4 | 5 | 0 |
| Withdrew: Adverse event | 3 | 10 | 1 |
| Withdrew: Subject non-compliance | 1 | 4 | 0 |
| Withdrew: Physician decision | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Serum ca >/=11.0mg/dl | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Administrative reasons | 0 | 1 | 0 |
Number of subjects in the intent to treat population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders
| participants | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | 34 | 66 | 30 |
Number of subjects in the per protocol population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders
| participants | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | 34 | 64 | 29 |
Number of Participants in the Intent to Treat Population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)
| participants | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT) | 87 | 124 | 38 |
Number of Participants in the per protocol population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)
| participants | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT) | 86 | 120 | 37 |
Collected over 6 months from initiation of treatment through end of treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | — | 18/103 (17.5%) | 36/103 (35%) |
| CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | — | 33/153 (21.6%) | 54/153 (35.3%) |
| CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | — | 9/42 (21.4%) | 22/42 (52.4%) |
| Event | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 3/103 | 2/153 | 1/42 |
| DiarrhoeaGastrointestinal disorders | 0/103 | 0/153 | 1/42 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/103 | 0/153 | 1/42 |
| CellulitisInfections and infestations | 1/103 | 2/153 | 1/42 |
| Urinary tract infectionInfections and infestations | 1/103 | 2/153 | 1/42 |
| Blood creatinine phosphokinase MB increasedInvestigations | 0/103 | 0/153 | 1/42 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/103 | 0/153 | 1/42 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/103 | 1/153 | 1/42 |
| EncephalopathyNervous system disorders | 0/103 | 0/153 | 1/42 |
| Hypoglcaemic seizureNervous system disorders | 0/103 | 0/153 | 1/42 |
| Event | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive |
|---|---|---|---|
| HyperphosphatemiaMetabolism and nutrition disorders | 2/103 | 3/153 | 4/42 |
| NauseaGastrointestinal disorders | 8/103 | 5/153 | 2/42 |
| OedemaGeneral disorders | 2/103 | 2/153 | 3/42 |
| Blood creatinine increasedInvestigations | 3/103 | 6/153 | 3/42 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/103 | 3/153 | 3/42 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/103 | 0/153 | 3/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/103 | 4/153 | 3/42 |
| HypertensionVascular disorders | 4/103 | 6/153 | 3/42 |
| AnaemiaBlood and lymphatic system disorders | 7/103 | 9/153 | 2/42 |
| ConstipationGastrointestinal disorders | 7/103 | 6/153 | 0/42 |
Intent to treat population: includes subjects receiving CTAP101 capsules only in the extension trial (up to 6 months total active therapy, subjects receiving up to 12 months receiving CTAP101 capsules (6 months in the previous trials and up to 6 months in the extension) with or without being randomized to CTAP101 capsules plus adjunctive therapy.
| Age, Continuous(years) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Monotherapy; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 10.78 | 66.9 ± 9.83 | 65.0 ± 12.34 | 65.9 ± 10.56 |
| Sex: Female, Male(Participants) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Monotherapy; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | Total |
|---|---|---|---|---|
| Female | 55 | 85 | 14 | 154 |
| Male | 48 | 68 | 28 | 144 |
| Region of Enrollment(participants) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | CTAP101 Capsules (Monotherapy; 12 Mos Treatment) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | Total |
|---|---|---|---|---|
| United States | 103 | 153 | 42 | 298 |
No study locations are listed for this record.
The record gives a start of Apr 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 3 months after primary completion. A results delay was requested in Jun 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Modified-release Calcifediol Capsule
Renal Insufficiency, Chronic →